SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2020
Commission File Number: 001-38067
Verona Pharma plc
(Translation of registrant's name into English)
3 More London Riverside
London SE1 2RE UK
+44 203 283 4200
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On March 16, 2020, Verona Pharma plc issued a press release (the "Notice of AGM Announcement") reporting that a hard copy of the Annual Report and Accounts for the year ended December 31, 2019, the Notice of Annual General Meeting and a Form of Proxy have been mailed to Shareholders of record as of March 13, 2020.
The Annual General Meeting of Verona Pharma will be held at the offices of Shakespeare Martineau at 60 Gracechurch Street, London, EC3V 0HR, United Kingdom at 10.30 a.m. on April 16, 2020.
The Notice of AGM Announcement is furnished herewith as Exhibit 1.1 to this Report on Form 6-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
VERONA PHARMA PLC
Date: March 30, 2020
/s/ Claire Poll
2019 Annual Report and Accounts and Notice of AGM March 16, 2020, LONDON – Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to confirm that a hard copy of the Annual Report and Accounts for the year ended December 31, 2019 ("2019 Annual Report and Accounts"), the Notice of Annual General Meeting and a Form of Proxy have been mailed to Shareholders of record as of March 13, 2020. Verona Pharma confirms that a copy of the 2019 Annual Report and Accounts and Notice of Annual General Meeting are available within the Investors section of its website, www.veronapharma.com. The Annual General Meeting of Verona Pharma will be held at the offices of Shakespeare Martineau at 60 Gracechurch Street, London EC3V 0HR, United Kingdom at 10.30 a.m. on April 16, 2020. -Ends- About Verona Pharma Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Verona Pharma is currently in Phase 2 development with three formulations of ensifentrine for the treatment of COPD: nebulized, dry powder inhaler, and pressurized metered-dose inhaler. Ensifentrine also has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com. For further information, please contact: Verona Pharma plc Tel: +44 (0)20 3283 4200 Victoria Stewart, Director of Communications email@example.com N+1 Singer Tel: +44 (0)20 3283 4200 (Nominated Adviser and UK Broker) Aubrey Powell / George Tzimas / Iqra Amin (Corporate Finance) Tom Salvesen (Corporate Broking) Optimum Strategic Communications Tel: +44 (0)20 950 9144 (European Media and Investor Enquiries) firstname.lastname@example.org Mary Clark / Eva Haas / Hollie Vile Argot Partners Tel: +1 212-600-1902 (US Investor Enquiries) email@example.com Stephanie Marks / Kimberly Minarovich / Michael Barron